secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105914
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q3 net loss $69.4M; SOL-R hits 555 subjects; cash ~$790M with offering
--------------------------------------------------------------------------------

- Net loss $(69.4)M ($0.38 loss per share) vs $(36.5)M loss in Q3 2024; revenue $14.5M, down 5.8% YoY.
- SOL-R registrational trial in wet AMD achieved target randomization of 555 subjects; topline data on track for 1H 2027.
- Cash balance $344.8M at Sep 30, plus ~$445M net proceeds from Oct equity offering providing runway into 2028.
- HELIOS Phase 3 program for AXPAXLI in NPDR to start imminently using novel DRSS endpoint.
- R&D expenses rose to $52.4M from $37.1M due to clinical trial costs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/0001104659-25-105914-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105914

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer